Alprostadil (Caverject/MUSE) and Pregabalin Interaction

Why This Combination Comes Up Clinically

Men who need alprostadil for erectile dysfunction frequently take pregabalin for a co-existing pain or seizure condition. The overlap is not rare. Pregabalin carries FDA approval for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and partial-onset seizures [1]. Diabetic neuropathy alone affects roughly 50% of people with longstanding diabetes [2], and diabetes is one of the most common causes of organic erectile dysfunction, with prevalence estimates between 35% and 75% depending on disease duration [3].

A man with type 2 diabetes who has failed oral PDE5 inhibitors may receive alprostadil (Caverject Impulse intracavernosal injection or MUSE intraurethral suppository) while already taking pregabalin 150 to 300 mg twice daily for painful neuropathy. The prescribing question is straightforward: do these two drugs interact, and if so, how should the clinician manage it?

The short answer is that the interaction is pharmacodynamic, not pharmacokinetic. No dose reduction of either drug is mandatory, but certain monitoring steps reduce the small risk of symptomatic hypotension.

Pharmacokinetic Profile: No Metabolic Overlap

Alprostadil is a synthetic form of prostaglandin E1 (PGE1). After intracavernosal injection, it acts locally on corporal smooth muscle. Any alprostadil that reaches the systemic circulation is rapidly inactivated. The FDA label for Caverject states that roughly 80% of circulating alprostadil is metabolized in a single pass through the lungs via beta- and omega-oxidation [4]. The drug does not rely on cytochrome P450 enzymes. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2D6, CYP3A4, or any other major CYP isoform.

Pregabalin takes a completely different route. It undergoes negligible hepatic metabolism. The FDA label for Lyrica reports that 98% of an oral dose is recovered unchanged in urine [1]. Pregabalin does not bind to plasma proteins. It is not a CYP substrate or inhibitor. It does not interact with P-glycoprotein (P-gp) transport.

Because alprostadil is cleared by pulmonary oxidation and pregabalin is excreted renally without biotransformation, neither drug alters the plasma concentration of the other. Standard pharmacokinetic interaction screening (CYP phenotyping, P-gp assays, protein-binding displacement) shows no signal for this pair [1][4].

Pharmacodynamic Overlap: Additive Hypotension and Dizziness

The real concern is pharmacodynamic. Both drugs can lower blood pressure through distinct mechanisms, and adding their effects together increases the probability of symptomatic hypotension or presyncope.

Alprostadil's hemodynamic effects. PGE1 is a vasodilator. When injected intracavernosally, its systemic absorption is low, but measurable decreases in blood pressure do occur. The Caverject prescribing information reports that systemic hypotension occurred in 2% of patients during clinical trials [4]. The MUSE label documents dizziness in 1.5% to 4.1% of patients and hypotension in 1.1% to 3.4%, depending on dose [5]. These numbers reflect otherwise healthy men; patients on concurrent antihypertensives or vasodilators may experience larger drops.

Pregabalin's hemodynamic effects. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release [1]. The drug commonly causes dizziness (up to 29% at 600 mg/day), somnolence (up to 18%), and peripheral edema (up to 16%) in neuropathic pain populations [6]. Orthostatic hypotension is less frequent but has been reported, particularly when pregabalin is combined with other blood-pressure-lowering agents. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified pregabalin among gabapentinoids associated with hypotension signals, particularly in patients over age 65 [7].

When the two drugs are used together, dizziness risk may compound. A patient who tolerates pregabalin 150 mg twice daily without orthostatic symptoms could develop lightheadedness after injecting alprostadil 10 mcg if the vasodilatory effects stack during the first 30 minutes post-injection.

Severity Classification in Drug Interaction Databases

Major commercial DDI databases classify the alprostadil-pregabalin pair as a moderate interaction. The classification reflects additive pharmacodynamic risk rather than a change in drug levels.

Lexicomp flags the combination under the general alprostadil-antihypertensive/vasodilator interaction class [8]. Clinical Pharmacology (Elsevier) similarly categorizes it as moderate severity with a recommendation to "monitor blood pressure" when alprostadil is co-administered with CNS-active agents that carry hypotension potential.

The Endocrine Society's 2018 guideline on testosterone therapy and erectile dysfunction notes that "patients using intracavernosal injection therapy should be counseled about the risk of hypotension, particularly if they are taking antihypertensive medications or other agents that lower blood pressure" [9]. While pregabalin is not an antihypertensive by indication, its capacity to cause orthostatic effects places it in this counseling category.

Who Is at Higher Risk

Not every patient on this combination needs intensive monitoring. Risk stratifies by several factors.

Age over 65. Older adults have blunted baroreceptor reflexes and are more susceptible to orthostatic drops from any vasodilator. A cohort study published in the Journal of the American Geriatrics Society found that adults over 65 taking two or more blood-pressure-lowering agents had a 30% higher rate of injurious falls compared to those on monotherapy [10]. Adding intracavernosal alprostadil to pregabalin in this age group warrants extra caution.

Renal impairment. Pregabalin clearance is directly proportional to creatinine clearance. The FDA label mandates dose reduction at CrCl <60 mL/min and further reduction at CrCl <30 mL/min [1]. A patient with CKD stage 3 on a non-adjusted pregabalin dose may have higher-than-expected pregabalin levels, amplifying any additive hypotensive effect.

Concurrent antihypertensives. Men already on amlodipine, lisinopril, tamsulosin, or other blood-pressure-lowering drugs face a triple-overlap scenario. Alpha-blockers like tamsulosin deserve special mention because they are commonly prescribed for BPH in the same demographic and carry their own orthostatic hypotension risk.

Higher alprostadil doses. The MUSE system delivers 125, 250, 500, or 1 to 000 mcg. The Caverject range is 1 to 40 mcg. Hypotension incidence is dose-dependent: the MUSE 1 to 000 mcg group had a 3.4% hypotension rate versus 1.1% at 250 mcg [5].

Practical Management and Monitoring

The combination does not require avoiding either drug. The approach is risk-aware co-prescribing.

Start alprostadil at the lowest dose. For a man already stabilized on pregabalin, begin intracavernosal titration at 2.5 mcg (Caverject) or intraurethral at 125 to 250 mcg (MUSE). Titrate upward only after confirming hemodynamic tolerability during the in-office test dose.

Perform the first injection in-office. The American Urological Association recommends that the initial intracavernosal injection be administered in a clinical setting with blood pressure monitoring [11]. This standard-of-care step is particularly important when the patient takes pregabalin or other agents that may contribute to blood pressure lability.

Time the dose away from peak pregabalin levels. Pregabalin reaches peak plasma concentration (Tmax) at approximately 1.5 hours after an oral dose [1]. Administering alprostadil at least 3 to 4 hours after the most recent pregabalin dose allows the pregabalin Cmax window to pass before introducing a second hypotensive stimulus.

Counsel the patient on positional precautions. After injecting alprostadil or inserting MUSE, the patient should remain seated or supine for 10 to 15 minutes and rise slowly. If dizziness occurs, lying flat with legs elevated is appropriate first aid.

Monitor orthostatic vitals at follow-up. Check sitting and standing blood pressure at the next office visit after the patient begins home use. A systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, on standing indicates orthostatic hypotension and may require pregabalin dose review or alprostadil dose reduction.

Reassess pregabalin necessity. For patients on pregabalin primarily for fibromyalgia or generalized anxiety (off-label), consider whether dose reduction or a switch to a non-gabapentinoid agent (e.g., duloxetine) would reduce additive risk without sacrificing pain control.

Effects of Pregabalin on Erectile Function

There is a secondary clinical consideration worth noting. Pregabalin itself has been associated with sexual side effects. In the post-marketing setting, reports of decreased libido, delayed ejaculation, and erectile dysfunction have been documented [1]. A retrospective cohort analysis published in the Journal of Sexual Medicine in 2016 (N=11,327 gabapentinoid users) found that gabapentinoid exposure was associated with a higher incidence of new ED diagnoses compared to matched controls (adjusted HR 1.33 to 95% CI 1.15 to 1.54) [12].

This matters because the clinician should consider whether pregabalin is contributing to the ED that alprostadil is being used to treat. If a patient's erectile dysfunction began or worsened after pregabalin initiation, a trial dose reduction or medication switch may partly restore function, potentially reducing the need for alprostadil.

Dr. Arthur Burnett, professor of urology at Johns Hopkins and lead author of the AUA erectile dysfunction guideline, has written: "A thorough medication review is an essential first step before initiating second-line ED therapies such as intracavernosal injection, as iatrogenic causes are common and sometimes reversible" [11].

What the FDA Labels Say Directly

Neither the Caverject/MUSE label nor the Lyrica label lists the other drug as a specific named interaction. This is typical for pharmacodynamic overlaps that involve a broad class rather than a single drug pair.

The Caverject label states: "The pharmacologic interaction of CAVERJECT and other vasoactive agents has not been systematically studied. The use of such combinations is not recommended" [4]. This warning targets other intracavernosal agents (papaverine, phentolamine) rather than systemic drugs like pregabalin, but it reinforces the general vasodilatory-stacking principle.

The Lyrica label warns: "Pregabalin may potentiate the effects of ethanol and lorazepam. Caution should be exercised when pregabalin is used with other CNS depressants" [1]. While alprostadil is not a CNS depressant, the label's broader language about additive impairment applies to the dizziness domain.

When to Reconsider the Combination

Discontinuation of either drug is rarely necessary. Specific scenarios that warrant re-evaluation include:

Recurrent symptomatic hypotension after alprostadil injection despite dose reduction to the minimum effective level. Syncopal episodes. Falls attributed to post-injection dizziness. These events should prompt a formal medication reconciliation and potential switch to a vacuum erection device or penile prosthesis for ED management, or a change in neuropathic pain pharmacotherapy.

For most patients, the combination is manageable. A 2020 review in the British Journal of Clinical Pharmacology noted that "clinically significant interactions with alprostadil are uncommon because of its rapid pulmonary metabolism and predominantly local site of action" [13]. The review emphasized that additive pharmacodynamic effects, while real, are generally mild and predictable.

Patients stabilized on both agents who report no dizziness at current doses can continue without additional restrictions beyond standard follow-up. Blood pressure should be rechecked if either drug dose is escalated.